Compare SIFY & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIFY | TBPH |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 1999 | N/A |
| Metric | SIFY | TBPH |
|---|---|---|
| Price | $14.84 | $19.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $27.80 |
| AVG Volume (30 Days) | 80.7K | ★ 368.8K |
| Earning Date | 01-12-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.58 |
| Revenue | ★ $473,538,214.00 | $80,327,000.00 |
| Revenue This Year | N/A | $70.90 |
| Revenue Next Year | $12.91 | N/A |
| P/E Ratio | ★ N/A | $33.66 |
| Revenue Growth | 6.85 | ★ 27.12 |
| 52 Week Low | $3.50 | $7.90 |
| 52 Week High | $17.85 | $21.03 |
| Indicator | SIFY | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 52.46 | 50.55 |
| Support Level | $14.07 | $18.45 |
| Resistance Level | $15.19 | $19.71 |
| Average True Range (ATR) | 0.85 | 0.80 |
| MACD | -0.12 | -0.10 |
| Stochastic Oscillator | 51.05 | 51.63 |
Sify Technologies Ltd is a provider of corporate network services in India. It offers converged Information and Communication Technology (ICT) solutions comprising Network- Connectivity services, Data Center services and Digital Services which include Cloud and Managed services, Applications Integration services and Technology Integration services. The company operates in three segments; Network Connectivity services which consists of domestic data, international data, wholesale voice. Data Center Services which consists of co-location services, cross connects and other allied managed services. Digital Services which consists of Cloud and Managed Services, Network Managed Services, Applications Integration Services, Technology Integration Services. Key revenue is from Network.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).